NCT05816122: MS-DETECT

MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect

Active, enrolled NA Last updated 13 June 2025

What this trial tests

NA trial testing MSCopilot® Detect mobile application in Multiple Sclerosis in 336 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

22 September 2023

Primary endpoint
31 May 2027

31 May 2027

Quick facts

Lead sponsor	Ad scientiam
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	336
Start date	22 September 2023
Primary completion	31 May 2027
Estimated completion	31 May 2027
Sites	34 locations across Denmark, France, Italy, Germany, Canada, United States, Spain

Drugs / interventions tested

• MSCopilot® Detect mobile application

Conditions studied

• Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

Ad scientiam

Who can join

Adults 30 to 65, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS).

The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Worsening (RAW) or Progression Independent of Relapses (PIRA). The study also aims to assess the safety, usability, and satisfaction of the solution.

A secondary objective is to determine MSCopilot® Detect's ability to provide early detection of disease changes and predict changes in Expanded Disability Status Scale (EDSS) scores in more patients.

Exploratory objectives include evaluating the relationship between MSCopilot® Detect composite and individual scores and other biomarkers such as MRI, soluble glial fibrillary acidic protein (sGFAP), and soluble neurofilament light chain (sNfL).

Patients will be able to download the free MSCopilot® Detect app. They will participate in 1 inclusion visit and 3 follow-up visits, scheduled at 6 months, 12 months, and 18 months (an additional visit at 24 months may be scheduled if necessary). Every 3 months, patients will complete validated questionnaires regarding MS symptoms and quality of life and participate in digital tests designed to monitor MS symptom progression.

The study will include 336 MS patients and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France

Publications & conference data

No peer-reviewed publications indexed yet for this trial.